ImmunoPrecise Announces Breakthrough in Dengue Vaccine Research Using LENSai™ Platform
ImmunoPrecise Antibodies Ltd has announced a significant breakthrough in dengue vaccine research. Using its proprietary LENSai™ platform, powered by patented HYFT® technology, the company has discovered an epitope conserved across all four known dengue virus serotypes.
This highly stable region of the virus offers a promising foundation for a potential universal dengue vaccine.
The discovery was made entirely using computational methods. It involved the identification of a virus segment called an epitope that remains unchanged across the four dengue serotypes (DENV-1 to DENV-4).
This finding is critical, as infection with one serotype does not protect against the others, making a universal target essential for effective vaccine development.
Unlike traditional laboratory-based techniques, ImmunoPrecise's LENSai platform carries out its analysis purely in silico. By applying AI models rooted in biological data, the platform rapidly pinpointed the conserved epitope using HYFT patterns.
These patterns link sequence-level information with structural insights, making it possible to predict three-dimensional features of proteins without laboratory imaging techniques such as X-ray crystallography or cryo-electron microscopy.
Early-stage research is also exploring its application in oncology, particularly for designing vaccines that target tumour-specific neoantigens.
It also demonstrates that AI-native technologies can offer solutions to complex challenges in immunology and drug discovery, opening the door to faster responses in future outbreaks and advancing personalised medicine strategies in cancer treatment.
This streamlined workflow is a step forward in modern vaccinology, providing a platform for future development of broad-spectrum and precision-based therapies.
